Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 MPC-150-IM (rexlemestrocel-L; Mesoblast) Drug Analysis -

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: MPC-150-IM" drug pipelines has been added to's offering.

MPC-150-IM (rexlemestrocel-L; Mesoblast) consists of highly purified, immunoselected mesenchymal precursor cells (MPCs). These cells release a range of molecules that stimulate both blood vessel growth and regeneration of heart muscle, while also reducing scar formation and harmful inflammatory responses within the damaged tissues. These rare cells are isolated from tissues around the donor's blood vessels and then expanded in large numbers before being administered to patients.

Product Profiles

MPC-150-IM: Chronic heart failure (CHF)

List of Figures

Figure 21: Drug assessment summary of Farxiga for chronic heart failure

Figure 22: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: MPC-150-IM drug profile

Table 2: MPC-150-IM's late-phase trials in chronic heart failure

Table 3: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.